FDA Approves AI-Powered Breast Cancer Screening Tool • The Register

An AI application that aids in the early detection of breast cancer has been cleared for commercialization by the U.S. Food and Drug Administration, software developer MedCognetics announced this week.

Texas-based MedCognetics has developed a cloud-based software-as-a-service system for radiologists that analyzes mammograms. The system runs QmTRIAGE, the company’s breast cancer screening tool, which just received 510(k) clearance from the FDA.

QmTRIAGE is based on computer vision algorithms trained to estimate breast tissue density to detect things like cysts or cancer-associated tumors in mammography scans. Radiologists must carefully review these scans to determine if a patient needs a follow-up biopsy to test for breast cancer. MedCognetics believes its tool will help radiologists by highlighting breast tissue that needs further examination.

“It will contribute to cost and time savings, reducing the time it takes a radiologist to review a case by 30 to 50 percent,” claimed MedCognetics CEO Debasish ‘Ron’ Nag in a statement The registry. This is an important factor as the demand for radiologists far exceeds the supply and burnout in the profession is widespread.

“The vast majority of early-stage cancers have no clinical signs – they are detected on a screening mammogram before the woman shows any symptoms. The only cure for breast cancer today is early detection. To make that possible, you have to think outside the box, and that’s what MedCognetics is doing,” he added.

FDA 510(k) clearance allows the company to begin commercializing QmTRIAGE and work with healthcare providers to get the tool up and running in clinical settings. Nag informed us that trial versions of the software will be launched in the US in 2023 and tests in other countries are on the agenda.

MedCognetics has partnered with researchers at the University of Texas Southwestern Medical Center (which has licensed some of its intellectual property to MedCognetics) and the University of Texas at Dallas to obtain clinical data to train its AI-powered algorithms.

Nag said medical AI models are often trained on small data sets that aren’t representative of patient populations, making them less effective for people of different ethnicities. He said the data used to train MedCognetics’ systems is more diverse, and the company is keen to work with more medical institutions to train its systems and test for more breast cancer scans.

“The ability to expose the AI ​​system to different sources and further variations of patient mammography cases will help further solidify performance,” MedCognetics explains on its website. This can be done by providing anonymized patient cases and, where appropriate, accompanying results from radiology and pathology reports.”

The company hopes to begin deploying its systems in commercial environments in 2023 and publish peer-reviewed articles demonstrating QmTRIAGE’s performance. ®

https://www.theregister.com/2022/12/15/fda_approves_ai_breast_cancer_tool/ FDA Approves AI-Powered Breast Cancer Screening Tool • The Register

Rick Schindler

World Time Todays is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@worldtimetodays.com. The content will be deleted within 24 hours.

Related Articles

Back to top button